SAB Biotherapeutics slumps as NIH halts trial of COVID drug candidate

SAB Biotherapeutics

02/03/2022 14:15

** SAB Biotherapeutics' shares  SABS.O  fall nearly 13% to
$4.00 premarket as National Institutes of Health discontinues
enrollment in the company's late-stage trial of COVID-19 drugs,
including its candidate SAB-185  urn:newsml:reuters.com:*:nGNX7Vkk35
    ** SABS adds enrollment discontinued due to low
hospitalization and death rates in the trial, which made it
difficult to get statistically significant data with existing
study design
    ** Stock had fallen 41% up to last close

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))